Newsletter - Hamlet BioPharma

Mar

30

2026

Pressrelease – Lund, March 30th, 2026 – Hamlet BioPharma presented at the Financial Stockholm event on March 26, 2026

Hamlet Biopharma

|

Hamlet BioPharma AB, an innovative pharmaceutical company developing new therapies for cancer and infections, announces that the company presented its...

Mar

24

2026

Pressrelease – Lund, 24 Mars, 2026 – Hamlet BioPharma tillförs cirka 8.5 miljoner kronor genom teckning av teckningsoptioner serie TO5B, s.k. korta optioner

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet BioPharma, ett innovativt läkemedelsbolag som utvecklar nya terapier mot cancer och infektioner, meddelar att bolaget tillförs cirka 8.5 miljon...

Mar

17

2026

Pressrelease – Lund, March 17th, 2026 – Hamlet BioPharmas digital monthly investor meeting on the 18th of March

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet BioPharma invites you to our monthly investors’ meeting to be held on the 18th of March 2026, at 12:00. Please click on the link below to parti...

Mar

15

2026

Pressrelease – Lund, 15 mars 2026 – Styrelsen beslutar om justering av villkoren för teckningsoptioner av serie TO5B och inför ny kompletterande teckningsperiod 16-23 mars 2026

Hamlet Biopharma

|

Newsletter, Press releases

Lund, 15 mars 2026, Hamlet BioPharma, ett innovativt läkemedelsbolag som utvecklar nya terapier mot cancer och infektioner, meddelar att styrelsen har...

Mar

09

2026

Nyhetsbrev – Hamlet BioPharma har undertecknat ett Letter of Intent avseende ett potentiellt kommersiellt avtal avseende Alpha 1H

Hamlet Biopharma

|

Newsletter, Press releases

Som tidigare meddelats har Hamlet BioPharma, tillsammans med det helägda dotterbolag Alpha1H BC AB (A1HB) och samarbetspartnern Linnane Pharma AB, und...

Mar

08

2026

PRESS RELEASE – Lund, March 8, 2026 – Hamlet BioPharma signed a Letter of Intent to outline terms of a potential collaboration and a commercial agreement concerning Alpha 1H

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet BioPharma AB (Hamlet), a clinical‑stage biopharmaceutical company advancing targeted oncological and other therapies, today announces that its ...

Feb

23

2026

Nyhetsbrev – Nature Microbiology publicerar banbrytande studie om icke-antibiotisk behandling av återkommande urinvägsinfektioner

Hamlet Biopharma

|

Newsletter, Press releases

Nature Microbiology publicerar banbrytande studie om icke-antibiotisk behandling av återkommande urinvägsinfektioner Hamlet BioPharma, det innovativa ...

Feb

18

2026

Newsletter – Catharina Svanborg featured in Global Digital Women’s Magazine

Hamlet Biopharma

|

Newsletter, Press releases

Catharina Svanborg featured in Global Digital Women’s Magazine Read the interview with Hamlet BioPharma’s founder Catharina Svanborg on Femest.com, p...

Feb

13

2026

Q2 Interim Report October – December 2025

Hamlet Biopharma

|

Financial, Newsletter, Press releases

...

Feb

12

2026

PRESS RELEASE – Lund, February 12th, 2026 – Nature Microbiology publishes the paper ‘’Targeted innate immune inhibition therapy compared with antibiotics for recurrent acute cystitis: a randomized, open-label phase 2 trial.’’

Hamlet Biopharma

|

Newsletter, Press releases

This groundbreaking study introduces an entirely new approach to managing recurrent urinary tract infections. Instead of killing the bacteria, the tre...

Feb

11

2026

PRESS RELEASE – Lund, February 11th, 2026 – Monthly investor meeting on the 13th of February when Hamlet BioPharma is releasing it’s Q2 report

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet BioPharma invites you to our February investors’ meeting to be held on the 13th of February 2026, at 12:00. Please click on the link below to p...

Feb

03

2026

PRESS RELEASE – Lund, February 3rd, 2026 – Collaboration agreement between Hamlet BioPharma and Immunoforge in South Korea

Hamlet Biopharma

|

Newsletter, Press releases

Hamlet BioPharma has signed an agreement with the Korean biotech company ImmunoForge, to develop novel administration technology for the peptide drug ...

Jan

27

2026

PRESS RELEASE – Lund 27 January 2026 – 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 𝗼𝗻 𝗡𝗼𝘃𝗲𝗹 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿

Hamlet Biopharma

|

Newsletter, Press releases

We warmly welcome you to the Symposium on “𝗡𝗼𝘃𝗲𝗹 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀 𝗳𝗼𝗿 𝗜𝗻𝗳𝗲𝗰𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗖𝗮𝗻𝗰𝗲𝗿.” The invited speakers are leading international scientists with...

Jan

16

2026

PRESSRELEASE – Lund 16 January 2026 – Invitation to digital meeting focusing on novel strategies for treating bacterial infections without antibiotics

Hamlet Biopharma

|

Newsletter, Press releases

Welcome to Hamlet BioPharma’s monthly digital meeting on January 21 at 12:00, held the same day as the Davos Summit discusses ‘’The Fragile Future of ...

Dec

18

2025

PRESSRELEASE – Lund 18 December, 2025 – The HAMLET project featured in Cancerfonden’s Christmas Campaign

Hamlet Biopharma

|

Newsletter, Press releases

The Swedish Cancer Society, Cancerfonden, is a powerful and important research support organization in Sweden. Based mainly on donations, Cancerfonden...

Dec

04

2025

Pressmeddelande – Lund 4 december, 2025 – Kommuniké från årsstämma i Hamlet BioPharma AB och efterföljande styrelsemöte

Hamlet Biopharma

|

Newsletter, Press releases

Vid årsstämma i Hamlet BioPharma AB, org.nr 556568-8958, (”Hamlet BioPharma” eller ”Bolaget”) den 4 december 2025 fattades de beslut som beskrivs neda...

Nov

14

2025

Nyhetsbrev – FDA ger Hamlet BioPharma pivotal status för avgörande Fas III studie i blåscancer

Hamlet Biopharma

|

Newsletter, Press releases

Federal and Drug Administration i USA (FDA) har som tidigare meddelats lämnat skriftlig feedback som stöder Hamlet BioPharmas planerade Fas III‑studie...

Nov

14

2025

Q1 Interim Report July – September 2025

Hamlet Biopharma

|

Financial, Newsletter, Press releases

...

Nov

13

2025

Hamlet BioPharma bjuder in till digitalt investerarmöte den 14 november 12.00

Hamlet Biopharma

|

Newsletter, Press releases

Klicka på länken nedan för att delta. Det går bra att ställa frågor till bolaget genom att e-posta dem till: fraga@investorstudios.se. Sändningen star...

Nov

12

2025

PRESSRELEASE – Lund 12 november, 2025 – Ny styrelsesammansättning stärker Hamlet BioPharma inför kommersialiseringsfas

Hamlet Biopharma

|

Newsletter, Press releases

Förslag ny styrelsesammansättning och ny ordförande Inför ordinarie årsstämma i Hamlet BioPharma föreslår större ägare omval av Catharina Svanborg, Ma...

Nov

10

2025

PRESS RELEASE – Lund, November 10th, 2025 – Hamlet BioPharma Receives FDA Pivotal-Study Feedback for Novel Neoadjuvant Therapy in Non–Muscle Invasive Bladder Cancer

Hamlet Biopharma

|

Newsletter, Press releases

HAMLET BioPharma, a clinical‑stage biopharmaceutical company advancing targeted oncological and other therapies, today announced it has received writt...

Nov

05

2025

Newsletter – Clinical study in infants with febrile kidney infection supports Hamlet BioPharma’s strategy for non-antibiotic treatment of bacterial infections

Hamlet Biopharma

|

Newsletter

One of the most comprehensive studies ever conducted in childhood urinary tract infection shows that a chaotic immune response causes symptoms and dam...

Nov

05

2025